Your browser doesn't support javascript.
loading
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Chen, Yi-Bin; Li, Shuli; Lane, Andrew A; Connolly, Christine; Del Rio, Candice; Valles, Betsy; Curtis, Morgan; Ballen, Karen; Cutler, Corey; Dey, Bimalangshu R; El-Jawahri, Areej; Fathi, Amir T; Ho, Vincent T; Joyce, Amy; McAfee, Steven; Rudek, Michelle; Rajkhowa, Trivikram; Verselis, Sigitas; Antin, Joseph H; Spitzer, Thomas R; Levis, Mark; Soiffer, Robert.
Afiliação
  • Chen YB; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ychen6@partners.org.
  • Li S; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lane AA; Division of Hematologic Malignancies, Dana-Farber Cancer Center, Boston, Massachusetts.
  • Connolly C; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Del Rio C; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Valles B; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Curtis M; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Ballen K; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Cutler C; Division of Hematologic Malignancies, Dana-Farber Cancer Center, Boston, Massachusetts.
  • Dey BR; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • El-Jawahri A; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Fathi AT; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Ho VT; Division of Hematologic Malignancies, Dana-Farber Cancer Center, Boston, Massachusetts.
  • Joyce A; Division of Hematologic Malignancies, Dana-Farber Cancer Center, Boston, Massachusetts.
  • McAfee S; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Rudek M; Division of Hematologic Malignancies, Dana-Farber Cancer Center, Boston, Massachusetts.
  • Rajkhowa T; Division of Hematologic Malignancies, Dana-Farber Cancer Center, Boston, Massachusetts.
  • Verselis S; Division of Hematologic Malignancies, Dana-Farber Cancer Center, Boston, Massachusetts.
  • Antin JH; Division of Hematologic Malignancies, Dana-Farber Cancer Center, Boston, Massachusetts.
  • Spitzer TR; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Levis M; Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, Maryland.
  • Soiffer R; Division of Hematologic Malignancies, Dana-Farber Cancer Center, Boston, Massachusetts.
Biol Blood Marrow Transplant ; 20(12): 2042-8, 2014 Dec.
Article em En | MEDLINE | ID: mdl-25239228

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Leucemia Mieloide Aguda / Mutagênese Insercional / Niacinamida / Inibidores de Proteínas Quinases / Tirosina Quinase 3 Semelhante a fms / Quimioterapia de Manutenção Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Leucemia Mieloide Aguda / Mutagênese Insercional / Niacinamida / Inibidores de Proteínas Quinases / Tirosina Quinase 3 Semelhante a fms / Quimioterapia de Manutenção Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2014 Tipo de documento: Article